| Schedule of Reconciles Segment Direct Profit or Loss |
The following table reconciles segment direct profit or loss to the Company’s consolidated results:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
(in thousands) |
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Research and development: |
|
|
|
|
|
|
|
|
|
|
|
QTORIN CMC |
$ |
3,308 |
|
|
$ |
1,517 |
|
|
$ |
5,135 |
|
|
$ |
2,289 |
|
QTORIN rapamycin for microcystic LM |
|
865 |
|
|
|
1,235 |
|
|
|
2,400 |
|
|
|
2,389 |
|
QTORIN rapamycin for angiokeratomas |
|
749 |
|
|
|
— |
|
|
|
1,201 |
|
|
|
— |
|
QTORIN rapamycin for cutaneous VM |
|
712 |
|
|
|
354 |
|
|
|
1,157 |
|
|
|
700 |
|
QTORIN rapamycin for microcystic LM - Government grant income |
|
— |
|
|
|
(212 |
) |
|
|
— |
|
|
|
(339 |
) |
Non-program specific and unallocated research and development expenses: |
|
|
|
|
|
|
|
|
|
|
|
Salaries and stock-based compensation |
|
3,697 |
|
|
|
1,501 |
|
|
|
6,887 |
|
|
|
2,823 |
|
Consultants |
|
2,081 |
|
|
|
385 |
|
|
|
3,434 |
|
|
|
632 |
|
Other |
|
1,061 |
|
|
|
338 |
|
|
|
1,593 |
|
|
|
698 |
|
Total research and development |
$ |
12,473 |
|
|
$ |
5,118 |
|
|
$ |
21,807 |
|
|
$ |
9,192 |
|
General and administrative: |
|
|
|
|
|
|
|
|
|
|
|
Salaries and stock-based compensation |
$ |
5,147 |
|
|
$ |
1,744 |
|
|
$ |
8,429 |
|
|
$ |
3,197 |
|
Consultants |
|
1,977 |
|
|
|
914 |
|
|
|
2,693 |
|
|
|
1,910 |
|
Other |
|
1,808 |
|
|
|
1,474 |
|
|
|
3,331 |
|
|
|
2,822 |
|
Total general and administrative |
$ |
8,932 |
|
|
$ |
4,132 |
|
|
$ |
14,453 |
|
|
$ |
7,929 |
|
Loss from operations |
$ |
(21,405 |
) |
|
$ |
(9,250 |
) |
|
$ |
(36,260 |
) |
|
$ |
(17,121 |
) |
|